本文翻译正在准备中。在此之前，我们暂时显示英文原文。
商业 · 2026/10/281 分钟阅读
Notice of Approval of Product Under Voucher: Material Threat Medical Countermeasure (MCM) Priority Review Voucher; Bixlenvo (Bictegravir and Lenacapavir)
本地自动翻译 · 来源原始语言
摘要
The Food and Drug Administration (FDA) is announcing the approval of a product redeeming a material threat MCM priority review voucher.
来源原始语言: Federal Register — Health and Human Services打开原始公告 →